Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFE3CT)

Drug Name

Alniditan Drug Info

Synonyms

UNII-B57Z82EOGE; B57Z82EOGE; 152317-89-0; [3H]alniditan; Alniditan [INN:BAN]; N-[[(2R)-chroman-2-yl]methyl]-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine; AC1Q4UFC; AC1L24EQ; GTPL117; GTPL120; SCHEMBL717887; CHEMBL88240; ZINC1536693; PDSP2_001383; PDSP1_001399; BDBM50403503; CS-6739; HY-101698; 2-((3-(((R)-2-Chromanylmethyl)amino)propyl)amino)-1,4,5,6-tetrahydropyrimidine; Pasmigren; R-091274

Indication

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Discontinued in Phase 3	[1]

Cross-matching ID

PubChem CID: 66004
CAS Number: CAS 152317-89-0
TTD Drug ID: DMFE3CT

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting 5-HT 1B receptor (HTR1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[3]
Eletriptan	DMW649X	Migraine	8A80	Approved	[4]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[4]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[4]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[4]
Naratriptan	DMO50U2	Headache	8A80-8A84	Approved	[5]
Prolixin decanoate	DMMJ1IS	Schizophrenia	6A20	Approved	[4]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[6]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[7]
[N-methyl-3H(3)]AZ-10419369	DMSCV02	Mood disorder	6A60-6E23	Phase 1	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting 5-HT 1D receptor (HTR1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[9]
Eletriptan	DMW649X	Migraine	8A80	Approved	[4]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[4]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[4]
Sumatriptan	DMVYXR8	Cluster headache	8A81.0	Approved	[10]
Rizatriptan	DMDJMA3	Migraine	8A80	Approved	[11]
Almogran	DM7I64Z	Migraine	8A80	Approved	[12]
Neu-P11	DMIQDFW	Alzheimer disease	8A20	Phase 2	[13]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[14]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1B receptor (HTR1B)	TTK8CXU	5HT1B_HUMAN	Agonist	[2]
5-HT 1D receptor (HTR1D)	TT6MSOK	5HT1D_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 120).
2	Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65.
3	Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
6	Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
7	Company report (NeurAxon)
8	5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
9	Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
10	Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
11	An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
12	Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
13	Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
14	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)